^
    Back
    Association details:
    Biomarker:TET1 mutation
    Cancer:Colorectal Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    347 - TET1 mutation as potential biomarker for immune checkpoint blockade in colorectal cancer

    Published date:
    03/10/2021
    Excerpt:
    The results were validated in a clinical cohort of immunotherapy, including 85 patients with colorectal cancer. The median overall survival was non-reached in 7 patients with TET1 mutations…